In the MSK MetTropism cohort, head and neck cancer and cervical cancer had the highest Nrf2-activating MUs frequency (6.07%), followed by cervical cancer (5.83%) and NSCLC (4.59%, Fig. 3B). This evidence concerns the gene NFE2L2 and cervical cancer.